Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Operations (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Cash from Operations data on record, last reported at 19330000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 187.14% year-over-year to 19330000.0; the TTM value through Dec 2025 reached 12451000.0, up 85.0%, while the annual FY2025 figure was 12451000.0, 85.0% up from the prior year.
  • Cash from Operations reached 19330000.0 in Q4 2025 per TARS's latest filing, up from 18257000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 20551000.0 in Q2 2021 and bottomed at 39335000.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 12912650.0, with a median of 14845000.0 recorded in 2022.
  • The widest YoY moves for Cash from Operations: up 903.72% in 2021, down 490.88% in 2021.
  • A 5-year view of Cash from Operations shows it stood at 12121000.0 in 2021, then increased by 10.29% to 10874000.0 in 2022, then plummeted by 261.73% to 39335000.0 in 2023, then soared by 43.61% to 22182000.0 in 2024, then surged by 187.14% to 19330000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 19330000.0 in Q4 2025, 18257000.0 in Q3 2025, and 29387000.0 in Q2 2025.